Recon: Fujifilm to spend $928M to expand Danish facility; AbbVie, Genmab partner on cancer therapy

• Coronavirus Vaccine Candidates’ Pivotal US Testing to Start This Summer (WSJ)
• Johnson & Johnson to begin human trials for coronavirus vaccine in late July, earlier than expected (CNBC)
• The coronavirus vaccine frontrunners have emerged. Here's where they stand (BioPharmaDive)
• Pharma Dealmakers, Sidelined in Pandemic, Are Ready for Comeback (Bloomberg)
• White House goes quiet on coronavirus as outbreak spikes again across the US (Politico)
• Price Limits Will Scare Off Covid Vaccine Makers, Fauci Warns (Bloomberg)
• Abbvie to partner with Genmab in $750 million cancer therapy deal (Reuters) (Press)
• Merck's bladder cancer late-stage study fails to meet main goals (Reuters)
• Retracted COVID-19 studies expose holes in vetting of data firms (Reuters)

• Europe to accelerate trials of gene-engineered COVID-19 vaccines – sources (Reuters)
• Six EU leaders urge greater collaboration to tackle future pandemics (Reuters)
• Singapore approves remdesivir drug for emergency COVID-19 treatment (Reuters)
• In the WHO’s Coronavirus Stumbles, Some Scientists See a Pattern (NYTimes)
• Japan's AnGes speeds towards 2021 rollout in coronavirus 'vaccine war' (Reuters)
• Short-Sellers Set Their Sights on Surging Asia Biotech Stocks (Bloomberg)
• Anti-inflammatory and cancer drugs tested in UK as possible COVID-19 therapy (Reuters)
• Indian firm Panacea says aiming to make COVID-19 vaccine (Reuters)
• Temasek-backed Tychan to start human trials next week for COVID-19 treatment (Reuters)
• Japan's Fujifilm to spend $928 million to double capacity of Danish drug facility (Reuters) (Endpoints)
• Sanofi sharpens focus on bispecifics, and China, with Alphamab deal (Endpoints)
• Many Canadian medical societies fail to disclose industry funding in their clinical guidelines (STAT)
• Russian factory recalls ventilator model linked to hospital fires (Reuters)

• Fauci Warns That the Coronavirus Pandemic Is Far From Over (NYTimes)
• Vaccine Makers Hedge Bets On Which One Will Emerge As Effective And Safe (NPR)
• Widespread mask-wearing could prevent COVID-19 second waves: study (Reuters)
• For virus-tamer Merkel, global alliances trumped nationalism (Reuters)
• WHO Americas director concerned about pandemic surging in new Latin America regions (Reuters)
• Brazil restores detailed COVID-19 data to national website (Reuters)
• The novel coronavirus attacks the lungs. A biotech company sees a common enzyme as key to protecting them (STAT)
• Illumina debuts next-generation sequencing test for COVID-19 (Fierce) (Reuters)
• Serum Institute investing USD 100 million on potential COVID-19 vaccine (Economic Times)
• Ex-FDA chief scientist slams 'chaos' caused by agency approach to antibody tests (MedtechDive)
• Ghana's Incas Diagnostics expects approval for COVID-19 antibody test (Reuters)
• Why Drug Companies May Resist Milking Covid-19 Treatments (WSJ)
• Cepheid developing test to distinguish COVID-19 from flu, RSV (MedtechDive)
• Coronavirus (COVID-19) Update: Daily Roundup June 9, 2020 (FDA)

• Bone Drugs May Have Added Benefit: Lower Pneumonia Risk (NYTimes)
• China says clinical trials show African swine fever vaccine safe so far (Reuters)
• Lilly pens antisense neuro pact with Evox Therapeutics (Fierce)
• Scientists create embryo-like research model from human stem cells (Reuters)
• FDA’s Scandal In Waiting? (Pink Sheet)
• Medical Care Costs Associated with Cancer Survivorship in the United States (AACR)
• US Biosimilars Market Is On Solid Footing, 10 Years In (Scrip)
• EU expands reach of Vertex' CF drug Kalydeco (PharmaTimes)
• UK Early Access Win For New Opdivo Indication (Pink Sheet)
• Pfizer offers 3rd round of JAK data, this time in kids. Can it compete? (Endpoints)
• Denali scoots past a setback with barely a scratch, quickly calling up a backup Alzheimer’s player on the bench (Endpoints)
• IPO bound? Five years in, Art Krieg and the Checkmate crew collect $85M to back up their 1-drug pipeline (Endpoints)
• Rare disease startup NFlection scores $20M in Series A haul; Gilead partner Galapagos signs pact with Oxford biotech (Endpoints)

• Medical device startup raises almost $44M to advance a less-invasive treatment for fluid in the brain (STAT)
• Siemens Healthineers, Geisinger ink 10-year digital health partnership (MedtechDive)
• Polish scientists design remote-controlled ventilator to fight COVID-19 (Reuters)
• MDR delay impact extends beyond European Union (Emergo)
• The European MDR and human factors engineering: Designing user-friendly software user interfaces and informational resources (Emergo)

• EMA SME office annual report 2019 (EMA)
• Harvard's Charles Lieber indicted for lying to the feds, bringing US researchers' China ties back to the spotlight (Endpoints)
• U.S. charges firm president, trader in COVID-19 fraud schemes (Reuters)
• FTC, Impax Spar At 5th Circ. Over Opana ER Deal (Law360)
• Merck Can't Wipe Out Microspherix's PTAB Win (Law360)